RxDoctor Payments Data

Vincent Codella, DO

Family Medicine · Union, NJNPI 1134111248

Payments from drug & device makers

$9,299in general payments, 2019–2025

Across 589 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$804
  • Lilly USA, LLC$796
  • Merck$541
  • GSK$461
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,262100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,299 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$200,462
Medicare patients
309
Services billed
2,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl30$41,279
JanuviaSitagliptin Phosphate20$26,393
EliquisApixaban18$11,635
EntrestoSacubitril/Valsartan22$8,610
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid17$4,453
Atorvastatin Calcium199$2,356
Budesonide13$1,824
Rosuvastatin Calcium72$1,466
Olmesartan Medoxomil33$1,413
Cinacalcet Hcl17$1,376
Fluticasone Propionate65$1,187
Metformin Hcl110$1,024
Amlodipine Besylate159$1,004
SynthroidLevothyroxine Sodium11$1,000
Pantoprazole Sodium48$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia$541$67,67250 claims
PfizerEliquis$438$11,63518 claims
NovartisEntresto$107$8,61022 claims
AbbVieSynthroid$251$1,00011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →